Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide
MBL2 single nucleotide polymorphism (SNP) associated with Grade 3 infection following cytotoxic chemotherapy. CD95 SNP associated with grade 3 infection following cytotoxic chemotherapy. CD95 SNP associated with mild neutrophilia and increased white blood cell count. Potential to identify patients likely to benefit from prophylactic colony stimulating factor therapy.